Showing 2531-2540 of 8673 results for "".
FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuThe Skin Science Podcast: Episode 1 - "The Skin Microbiome" with Doris Day, MD, FAAD, MA
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-skin-science-podcast-episode-1-the-skin-microbiome-with-doris-day-md-faad-ma/20067/Hosted by Thomas Hitchcock, Ph.D., Chief Science Officer at Crown Laboratories, The Skin Science Podcast is a monthly podcast that covers topics relating to skin health. The series will dig into hot topics within dermatology and aesthetics and will challenge the audience to think a bit differently aNew Drug Developments in Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-drug-developments-in-dermatology/19971/Despite the COVID pandemic, the FDA had a nearly record year in drug approvals, says Vinod Nambudiri, MD, MBA, which has translated to new developments in dermatology. He discusses approvals of tirbanibulin 1% ointment for actinic keratoses and clascoterone cream 1% for acne, and how they fit into tLive in Las Vegas: Get Ready for DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/live-in-las-vegas-get-ready-for-derm2021/19968/The DERM2021 NP/PA CME Conference offers dermatology physician assistants and nurse practitioners an opportunity to stay up to date on the latest products, drugs, and treatments in dermatology to improve care for patients. Joe Gorelick, MSN, FNP-BC, DEF President, says this year’s conference is goinRepresentation in Marketing and Outreach
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/representation-in-marketing-and-outreach/19916/There is an apparent low rate of participation in aesthetic procedures among patients of color. Does this reflect a lack of interest or does limited representation in marketing and educational materials leave patients feeling that aesthetic interventions aren't meant for them? Panelists discuss theAlmirall/Allergan, LEO/Bayer Deals
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-almirall-allergan-leo-bayer-deals/18240/Leo Pharma has agreed to acquire Bayer's global prescription dermatology unit, and Almirall will acquire Allergan's US portfolio of medical dermatology drugs. When it comes to patient engagement, aesthetic practices often have the right mindset, but they may lack the skills or time necessary to execValeant's Plan for Derm; VCS Highlights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-valeant-s-plan-for-derm-vcs-highlights/18587/Amid reports that its Obagi and Solta units may be sold off, Valeant Pharmaceuticals is assuring investors that the company is focused on the future and has plans to fix its dermatology unit. Vegas Cosmetic Surgery has wrapped up its 12th program, gathering dermatologists, plastic surgeons, facial pBiosimilar Recommended; Saunders to Head New Pfizer/Allergan Organization
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-biosimilar-recommended-saunders-to-head-new-pfizer-allergan-organization/18825/An FDA committee has recommended Pfizer's Inflectra, biosimilar to infliximab, developed by Celltrion. Sunbelt Melanoma Trial finds no benefit for IFN in Phase III melanoma. Pfizer/Allergan provides details on structure of new organization and announces leadership, including President and COO BrentFDA Warns on Expression; Lilly's Ixekizumab Data Promising
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-warns-on-expression-lilly-s-ixekizumab-data-promising/19093/Lilly's Ixekizumab phase III data look good for psoriasis, and the FDA warns on improper use of Expression hyaluronic acid as a dermal filler. Plus, Sitavig is available for herpes labialis, and Syneron's laser gets an onychomycosis clearance.The Safety of New Systemics
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/the-safety-of-new-systemics/33159/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, provides an overview of the safey of systemic therapies such as JAK inhibitors and other similar drugs, giving dermatologists a high-level look at what they need to help clinical decision-making.